Principal Financial Group
NMRA icon

Principal Financial Group’s Neumora Therapeutics NMRA Stock Holding History

Principal Financial Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,878
Closed -$166K – 2348
2024
Q2 		$166K Buy
+16,878
New +$175K ﹤0.01% 2168

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Principal Financial Group's NMRA Position: Q3 2024 in Review

Principal Financial Group sold out of Neumora Therapeutics (NMRA) in Q3 2024, closing a stake of 16,878 shares — an estimated $166K sold.

Principal Financial Group first reported a position in NMRA in Q2 2024 and held it in 1 quarter. The position peaked at $166K in Q2 2024. 104 funds tracked by Wall St. Rank hold NMRA as of Q3 2024.

  • Principal Financial Group reported no remaining Neumora Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 16,878 Neumora Therapeutics shares in Q3 2024, an estimated $166K.
  • Principal Financial Group first reported a position in Neumora Therapeutics in Q2 2024 and held it in 1 quarter.
  • Principal Financial Group's Neumora Therapeutics position peaked at $166K in Q2 2024.
  • 104 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.